An expert review and commentary on the efficacy and safety of tranexamic acid for the treatment of heavy menstrual bleeding

References

• Fraser IS, Langham S, Uhl-Hochgraeber K. The health-related quality of life and economic burden of abnormal uterine bleeding: a critical review. Expert Rev. Obstet. Gynecol. 4, 179–189 (2009).
   Google Scholar
• Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 10(3), 183–194 (2007).
   PubMed Web of Science ®Google Scholar
• Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am. J. Obstet. Gynecol. 190(5), 1224–1229 (2004).
   PubMedGoogle Scholar
• National Collaborating Centre for Women's and Children's Health. Heavy menstrual bleeding. Clinical Guideline. RCOG Press, London, UK (2007).
   Google Scholar
• Cohen BJ, Gibor Y. Anemia and menstrual blood loss. Obstet. Gynecol. Surv. 35(10), 597–618 (1980).
   PubMedGoogle Scholar
• Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf. 27(2), 75–90 (2004).
   PubMedGoogle Scholar
• Warner P, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray G. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management. BMJ 323(7303), 24–28 (2001).
   PubMedGoogle Scholar
• Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet. Gynecol. 114(5), 1041–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Hurskainen R, Grenman S, Komi I et al. Diagnosis and treatment of menorrhagia. Acta Obstet. Gynecol. Scand. 86(6), 749–757 (2007).
   PubMed Web of Science ®Google Scholar
• Aberdeen Endometrial Ablation Trials Group. A randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome at four years. Br. J. Obstet. Gynaecol. 106(4), 360–366 (1999).
   PubMedGoogle Scholar
• Edlund M. Nonhormonal treatments for heavy menstrual bleeding. J. Womens Health (Larchmt). 20(11), 1645–1653 (2011).
   PubMedGoogle Scholar
• Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 313(7057), 579–582 (1996).
   PubMedGoogle Scholar
• Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet. gynecol. 113(5), 1104–1116 (2009).
   PubMed Web of Science ®Google Scholar
• Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst. Rev. (4), CD000249 (2000).
   Google Scholar
• Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf. 31(4), 275–282 (2008).
   PubMedGoogle Scholar
• Rybo G. Tranexamic acid therapy effective treatment in heavy menstrual bleeding. Clinical update on safety. Ther. Advan. 4, 1–8 (1991).
   Google Scholar
• Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 63(13), 1417–1433 (2003).
   PubMed Web of Science ®Google Scholar
• OTC tranexamic acid for heavy menstrual bleeding? Drug Ther. Bull. 49(1), 6–8 (2011).
   PubMedGoogle Scholar
• Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int. J. Gynaecol. Obstet. 113(1), 3–13 (2011).
   PubMed Web of Science ®Google Scholar
• Eder S, Baker J, Gersten J, Mabey RG, Adomako TL. Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids. Women's health. 9(4), 397–403 (2013).
   PubMedGoogle Scholar
• Edlund M, Andersson K, Rybo G, Lindoff C, Astedt B, von Schoultz B. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br. J. Obstet. Gynaecol. 102(11), 913–917 (1995).
   PubMedGoogle Scholar
• Lukes AS, Freeman EW, Van Drie D, Baker J, Adomako TL. Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. Womens Health (Lond. Engl.). 7(5), 591–598 (2011).
   PubMedGoogle Scholar
• Freeman EW, Lukes A, VanDrie D, Maby RG, Gersten J, Adomako TL. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am. J. Obstet. Gynecol. 205(4), 319 e311–317 (2011).
   Google Scholar
• Kouides PA, Byams VR, Philipp CS et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br. J. Haematol. 145(2), 212–220 (2009).
   PubMed Web of Science ®Google Scholar
• Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J. Obstet. Gynaecol. 26(7), 673–678 (2006).
   PubMedGoogle Scholar
• Lin X, Gao ES, Li D, Zhang M, Dou LX, Yuan W. Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstet. Gynecol. Scand. 86(9), 1126–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. a double-blind trial. Br. Med. J. 4(5729), 214–216 (1970).
   PubMedGoogle Scholar
• Lukes AS, Moore KA, Muse KN et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet. Gynecol. 116(4), 865–875 (2010).
   PubMed Web of Science ®Google Scholar
• Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br. J. Obstet. Gynaecol. 102(5), 401–406 (1995).
   PubMedGoogle Scholar
• Lukes AS, Muse K, Richter HE, Moore KA, Patrick DL. Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. Curr. Med. Res. Opin. 26(11), 2673–2678 (2010).
   PubMed Web of Science ®Google Scholar
• Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). Acta Obstet. Gynecol. Scand. 46, 572–580 (1967).
   Web of Science ®Google Scholar
• Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet. Gynecol. Scand. 67(7), 645–648 (1988).
   PubMed Web of Science ®Google Scholar
• Vermylen J, Verhaegen-Declercq ML, Verstraete M, Fierens F. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb. Diath. Haemorrh. 20(3), 583–587 (1968).
   PubMedGoogle Scholar
• Moore KA, Morin I, Marenco T, Lavigne JR, Morelli G. Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. Am. J. Ther. 19, 190–198 (2011).
   Google Scholar
• Muse K, Mabey RG, Waldbaum A, Gersten JK, Adomako TL. Tranexamic acid increases hemoglobin and ferritin levels in women with heavy menstrual bleeding. J. Womens Health 21(7), 756–761 (2012).
   Google Scholar
• Muse K, Lukes AS, Gersten J, Waldbaum A, Mabey RG, Trott E. Long-term evaluation of safety and health-related quality of life in women with heavy menstrual bleeding treated with oral tranexamic acid. Womens Health (Lond. Engl.) 7, 699–707 (2011).
   PubMedGoogle Scholar
• de Souza SS, Camargos AF, Ferreira MC et al. Hemoglobin levels predict quality of life in women with heavy menstrual bleeding. Arch. gynecol. obstet. 281(5), 895–900 (2010).
   PubMedGoogle Scholar
• Weström L, Bengtsson LP. Effect of tranexamic acid (AMCA) in menorrhagia with intrauterine contraceptive devices. J. Reprod. Med. 5(4), 154–161 (1970).
   PubMedGoogle Scholar
• Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br. J. Obstet. Gynaecol. 90(1), 78–83 (1983).
   PubMedGoogle Scholar
• Lysteda®, package insert. Ferring Pharmaceuticals Inc, Parsippany, NJ (2010).
   Google Scholar
• Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 57(6), 1005–1032 (1999).
   PubMed Web of Science ®Google Scholar
• Cyklokapron®, package insert. Pfizer Australia Pvt Ltd, West Ryde, NSW (2010).
   Google Scholar
• Svahn CM, Schannong M, Stenberg U, Widlund L. Absorption of tranexamic acid as a prodrug in healthy volunteers. Arzneimittelforschung 38(5), 735–738 (1988).
   PubMedGoogle Scholar
• Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur. J. Clin. Pharmacol. 20(1), 65–72 (1981).
   PubMed Web of Science ®Google Scholar
• Eriksson O, Kjellman H, Pilbrant A, Schannong M. Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur. J. Clin. Pharmacol. 7(5), 375–380 (1974).
   PubMedGoogle Scholar
• Sindet-Pedersen S. Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. J. Clin. Pharmacol. 27(12), 1005–1008 (1987).
   PubMedGoogle Scholar
• Imbesi S, Nettis E, Minciullo PL et al. Hypersensitivity to tranexamic acid: a wide spectrum of adverse reactions. Pharm. World Sci. 32(4), 416–419 (2010).
   PubMedGoogle Scholar
• Prentice CR. Basis of antifibrinolytic therapy. J. Clin. Pathol. Suppl. (R. Coll. Pathol.). 14, 35–40 (1980).
   PubMedGoogle Scholar
• Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am. J. Pathol. 144(5), 855–861 (1994).
   PubMedGoogle Scholar
• Astedt B, Liedholm P, Wingerup L. The effect of tranexamic acid on the fibrinolytic activity of vein walls. Ann. Chir. Gynaecol. 67(6), 203–205 (1978).
   PubMedGoogle Scholar
• Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet. Gynecol. Scand. 73(3), 274–277 (1994).
   PubMed Web of Science ®Google Scholar
• Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 116(1), 91–97 (2009).
   PubMedGoogle Scholar
• Berntorp E. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb. Haemost. 86, 714–715 (2001).
   PubMed Web of Science ®Google Scholar
• Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. 354(4), 353–365 (2006).
   PubMedGoogle Scholar
• Moore KA, Callahan TS, Maison-Blanche P et al. Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding. Expert Opin. Pharmacother. 11(14), 2281–2290 (2010).
   PubMed Web of Science ®Google Scholar
• Theil PL. Ophthalmological examination of patients in long-term treatment with tranexamic acid. Acta. Ophthalmol. (Copenh.) 59(2), 237–241 (1981).
   Google Scholar
• Johnson NF, McKecknie N, Forrester JV. An investigation of retinal function and structure in rabbits treated long-term with tranexamic acid. Toxicol. Appl. Pharmacol. 40(1), 59–63 (1977).
   PubMedGoogle Scholar
• Cravens GT, Brown MJ, Brown DR, Wass CT. Antifibrinolytic therapy use to mitigate blood loss during staged complex major spine surgery: postoperative visual color changes after tranexamic acid administration. Anesthesiology 105(6), 1274–1276 (2006).
   PubMed Web of Science ®Google Scholar